Objective: To evaluate the clinical and cost impact of switching angiotensin receptor blockers (ARBs) to angiotensin-converting enzyme inhibitors (ACEIs) in patients with hypertension.
INTRODUCTION
A ngiotensin-converting enzyme inhibitors (ACEIs)/ angiotensin receptor blockers (ARBs) are recommended as the first-line treatment of hypertension by most of the international guidelines [1, 2] . Their increasing utilization has accounted for a significant part of total medicine use across Europe. From 2001 to 2007, ACEIs/ ARBs utilization significantly increased across six European countries [3] and contributed to a major part of the total increase of medicine expenditure [4] . In 2011, they accounted for 6% of all the prescribed medicines in the United Kingdom [5] . Consequently, many countries worldwide have initiated prescribing efficiency strategies to optimize the use of ACEIs/ARBs [3] .
In 2009, a Better Care Better Value (BCBV) prescribing indicator for ACEIs/ARBs was implemented in the UK [6] , which encouraged prescribers to initiate adults with hypertension on ACEIs and actively switch established ARB users to ACEIs whenever appropriate. A cost saving was expected to achieve by switching ARBs to ACEIs because of the differential cost between ARBs and ACEIs [7] . However, as ACEIs and ARBs have comparable effects in reducing cardiovascular disease (CVD) mortality and morbidity [8] , it Journal of Hypertension 2019, 37:1285-1293 a was also assumed that the 'therapeutic switching' between these two classes with a different mechanism of actions and active chemical entities [9] would not compromise the quality of care. However, this assumption is neither evidence-based nor has it been tested.
Previous studies demonstrated that policy-induced changes in prescribing patterns may not always translate into expected changes in patient outcomes [10] . Therefore, rigorous assessment of effects on patient outcomes is especially crucial given General Practitioners' concerns over potential deterioration in patients' quality of care that some anticipated to result from the policy-promoted switching of patients from ARBs to ACEIs [11] . Various factors that lead to failure in therapeutic switching and consequently jeopardize the clinical effectiveness of therapy [9] have been suggested in previous literature, including the lack of guidance for prescribers to implement the switching, and postswitching reduction in patients' adherence because of switching to a drug with a lower adherence profile [12] , patient's confusion and concerns resulting from changes in the drug's package, taste and/or appearance [13] , and patients' negative expectations about switching (nocebo effect) [14] . These factors could also apply to the switching of ARBs to ACEIs.
Consequently, the overall cost-saving from switching to a cheaper drug may be offset by spending elsewhere in the health care system, resulting from the implementation or management of the adverse consequences of the switching [15] . For example, administration costs, additional visits for dose titration, follow-up and laboratory tests required to implement the switching, and hospitalization costs needed to manage the consequence of inadequate blood pressure (BP) control [15] . Therefore, because of the lack of empirical evidence to support the therapeutic switching of ARBs to ACEIs, this study aimed to investigate the unanticipated impact of switching ARBs to ACEIs in adults with hypertension on adherence to ARBs and ACEIs, clinical effectiveness and overall changes in the National Health Service (NHS) costs.
METHODS

Study design and data source
This retrospective cohort study used the UK primary care dataset -the Clinical Practice Research Datalink (CPRD) [16] in linkage with the hospitalization dataset in Englandthe Hospital Episode Statistics (HES) [17] from April 2006 to March 2012. CPRD contains longitudinal electronic records (including patient demographics, medical diagnosis and prescribed medications) for about 8.5% of the UK population. It has been considered broadly representative regarding practice and patient characteristics in the UK [18] . In addition, 65% of the English practices in the CPRD consent to data linkage with the HES [19] . The study protocol was approved by the Independent Scientific Advisory Committee of CPRD (protocol number 13-150).
Study cohort
Adults (!18 years old) with primary hypertension, without a previous CVD and chronic kidney disease (CKD), and registered in the HES-consenting practices were identified by relevant Read codes (standard clinical terminology system used in the CPRD). Eligible patients who were issued with ARB during the study period were followed from their first ARB prescription date (index date) to the date when they switched to ACEIs (preswitching period), and then from the switching date to the date when study ended, patient left the dataset or died (postswitching period) whichever happened first. According to previous literature, switching was defined as discontinuation of ARB therapy and starting of ACEIs within a 'switching window' to equal the duration of one prescription supply [20] , which was 30 days on average in this study.
During the preswitching period, the study cohort was prescribed with only ARBs as antihypertensive treatment. Considering the effect of combining additional antihypertensive medications with ACEIs in the postswitching period, the study cohort was sub-grouped by whether other antihypertensive medicines were prescribed to ACEIs in the postswitching period into the ACEIs-combined and ACEIsmonotherapy group, respectively.
All the seven ARBs (losartan, candesartan, valsartan, telmisartan, irbesartan, olmesartan, eprosartan) and the 11 ACEIs (ramipril, enalapril, lisinopril, captopril, cilazapril, quinapril, fosinopril, imidapril, moexipril, trandolapril, perindopril) that were available in the UK during the study period were included in this study. As this study aimed to evaluate the impact of switching between the ARB and ACEI classes rather than individual ARBs and ACEIs, the types and daily dosages of the individual ARBs and ACEIs were not specified in the analysis. Given the relatively uncomplicated dosing schedules for ARBs and ACEIs in treating hypertension and evidence that general practitioners in the UK generally follow the recommendations in British National Formulary (BNF) [21, 22] , we assumed that ARBs/ACEIs were prescribed according to their recommended doses in the BNF.
Outcome measures
Adherence to antihypertensive medications, BP, hypertension-related complications and healthcare resource utilization and costs (Table 1) were measured in both the 'preswitching' and 'postswitching' period of the two study subgroups [23] [24] [25] [26] .
The proxy for adherence -the proportion of days covered (PDC) for ARBs and ACEIs were measured in the preswitching and postswitching period, respectively, by dividing the total number of days covered by the drug prescription by the number of days in the follow-up time in each period, and was truncated at 100% [27] . A standard cutoff point of 80% was applied to categorize the patient as adherent (PDC !80%) and nonadherent (PDC < 80%) [28] , then the proportion of nonadherent patients was estimated.
In each period, mean SBP and DBP were calculated as the average of the last three measurements. Furthermore, the incidence of individual and composite hypertensionrelated complications, including stroke, myocardial infarction (MI), angina, heart failure,and CKDs were identified by applying previously validated ICD-10 diagnosis codes [29] to hospitalization episodes in HES. hypertension-related healthcare resource utilization was collected from primary and secondary care settings (Table 1) . Individuals' resource utilization was multiplied by the assigned unit cost to obtain the overall direct annual medical cost for each patient in each period.
Covariates
Patients' baseline characteristics including demographics (age, sex), and clinical characteristics, for example, SBP, DBP, smoking status, BMI, serum cholesterol and comorbidity measured using the Charlson comorbidity index (CCI) [30] were obtained at the index date. Prevalent hypertension patients and prevalent ARBs uses were defined as having any hypertension diagnosis codes or prescribed ARBs in the year before the index date; otherwise classified as incident hypertension patients and user, respectively.
Data analysis
Baseline characteristics were reported by descriptive statistics (mean and standard deviation for continuous variables; frequency and proportions for categorical variables) and the differences between subgroups were tested by the unpaired t-test and chi-square test. Univariate analyses were undertaken in a self-controlled precomparison and postcomparison framework by applying appropriate statistical tests suitable for the outcome variables (Table 1) . Furthermore, multilevel, mixed-effects regression modelling [31] was used to compare adherence, BP and hypertension-related complications preswitching and postswitching, while adjusting for covariates. The results were presented as adjusted odds ratio (aOR) or adjusted mean difference (aMD) with their 95% confidence interval (CI). Patient's baseline characteristics (Table 2 ) such as age, sex and smoking were not included in the adjustment models as individuals acting as a control for themselves.
RESULTS
Baseline characteristics
About 5% (n ¼ 2304) of patients (n ¼ 46 193) who switched their antihypertensive medications were ARBs switchers; of which 45.7% (n ¼ 1053) switched from ARBs to ACEIs during the study period; of which, only 44.6% (n ¼ 470) patients were identified in the practices linked with HES, and hence were eligible for inclusion in this study. Patients in the ACEIs-combined (n ¼ 369; 78.5%) and ACEIs-monotherapy groups (n ¼ 101; 21.5%) had similar characteristics (Table 2) , except for significantly more nonsmokers in the ACEIs-combined group (58.0 vs. 47.5%, P < 0.05).
Proportion of days covered and proportion of nonadherent patients
Comparing the postswitching against preswitching period, the significant difference in adherence to antihypertensive medicating was only observed in the ACEIs-combined group. For example, the median PDC was significantly lower (99.2 vs. 97.9%, P < 0.001; Table 3 ); similarly, the proportion of nonadherent patients (PDC < 80%) was significantly higher (17.3 vs. 29.0%, P < 0.001), and consistently, a significantly higher postswitching likelihood of being nonadherent (aOR: 2.6; 95% CI: 1.6-4.1) was found in the multivariate regression (Table 3) .
Blood pressure
Likewise, a significant reduction in the mean SBP and DBP in the postswitching period were only observed in the ACEIs-combined group (Table 3) ; consistently, a significant postswitching reduction in both mean SBP [aMD (mmHg): À2.2; 95% CI: 3.5 to À1.0] and DBP (aMD: À2.1; 95% CI: 
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Incidence of hypertension-related complications
Of the 70 hypertension-related events identified from 40 patients; there was no significant difference in the incidence of individual or composite hypertension-related complications comparing postswitching against the preswitching period, except for a significantly lower incidence of MI in the postswitching period (13 vs. 3%, P < 0.001), which was only observed in the ACEIs-combined group. Consistently, the multivariate regression indicated no significant difference in risk of individual and composite hypertension-related complications, except for a significantly lower risk of MI (aOR: 0.1; 95% CI: 0.04-0.6) the postswitching period (Table 4) .
Healthcare resource utilization and costs
There was higher healthcare resource use identified in the postswitching period, except for a lower and nonsignificant number of hospitalizations (Table 5) . Overall, the median number of general practitioner consultations was higher in the postswitching period compared with the preswitching period, but this was statistically nonsignificant (4.1 vs. 3.6, P > 0.05). The total direct cost of healthcare resource utilization was significantly lower in the postswitching period ( Fig. 1) . The bootstrapping analysis indicated a significantly lower total mean annual cost per patient in the postswitching period (£630 vs. £300.9; mean difference: À£329.2; 95% CI: À534.6 to À205.7), regardless of stratifying the analysis by ACEIs-combined (mean difference: À£393.2; 95% CI: À665.3 to À242) or ACEIs-monotherapy group (mean differnce: À£95.1; 95% CI: À132.1 to À39.0; Table 6 ). This overall cost reduction was driven mainly by the significant decrease in the cost of antihypertensive drugs in the postswitching period. The costs of general practitioner consultations and outpatient clinic attendance were not significantly different between the preswitching and postswitching period.
DISCUSSION
This study investigated a crucial prescribing issue, which affects a large number of adult patients under the care of general practitioners by assessing the clinical and economic impact of the ARBs switching promoted by the BCBV policy. This study found that switching ARBs to ACEIs in adults with primary hypertension in current practice had no negative impact on medication adherence, clinical outcomes and resulted in an overall direct medical cost saving. The results suggested there was no concern over compromising patients' quality of care caused by ARBs switching to ACEIs. The small number of 'switchers' identified in this study indicates that switching hypertensive patients from ARBs to ACEIs appears to be uncommon in the UK. This could be attributed to the lack of an effective, national switching policy to promote switching ARB to ACEIs actively. Our previous study has shown that the BCBV indicator was ineffective [32] because of several implementation barriers [11] . Furthermore, the superior tolerability profile [33] and strong pharmaceutical marketing of ARBs [34] could also contribute to the low ARB-switching rate.
Although the previous literature has found that switching of antihypertensive drugs was associated with lower medication adherence; in this study, a significant reduction in postswitching adherence was only observed in the ACEIscombined group, which suggests that the reduced adherence was primarily associated with the additional antihypertensive drugs prescribed, that is, the complexity of therapeutic regime rather than the switching. The negative association between adherence and increasing the CKD, chronic kidney disease; HF, heart failure; IHD, ischaemic heart diseases; MI, myocardial infarction; NA, non-applicable as study subgroups did not develop the complications before or after the switching. a aOR, adjusted odds ratio, models were adjusted for patients' follow-up time, PDC, SBP and DBP, whether the patient developed the studied outcome of interest in the preswitching period. GPs consultation  Quantity  4359  5734  3277  5075  1082  659  Cost  126 361  103 493  111 716  86770  14 644  16 714  Antihypertensive drug prescription  Quantity  9347  14 120  6909  12 508  2438  1612  Cost  95 543  12 216  79 979  10 603  15 563  1614  Hospitalization  Quantity  46  33  45  28  1  5  Cost  73 147  23 800  73 931  21 237  216  2563  Outpatient attendance  Quantity  17  44  12  42  5  2  Cost  1060  1 891  878  1786  182  105  Total  Quantity  13 769  19 931  10 243  17 653  3526  2278  Cost  296 111  141 400  266 504  120 396  30 605  20 996 ACEIs, angiotensin-converting enzyme inhibitors.
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Journal of Hypertension www.jhypertension.comcomplexity of a therapeutic regimen [35] as a result of increasing the number of prescribed antihypertensive drugs [36] has been well-documented in the literature. In addition, the comparable adherence profile between ACEIs and ARB [12, 34, 37] and the increasing patient involvement in their healthcare decision that in UK healthcare settings [38, 39] could attribute to the lack of association between switching and adherence to ARB found in this study. The increase of patient involvement has been observed in several UK studies [40, 41] that evaluated medication switching, including the switching of antihypertensive drugs, and involving patients in their treatments is believed to improve patients' engagement and adherence to treatment regimen. Similar to the effect of ARBs switching on adherence, the significant reduction of both SBP and DBP was only observed in the ACEIs-combined group after switching. Since ARBs and ACEIs have similar efficacy in lowering BP [42] , this result also indicates that the reduction of BP may be related to factors other than the switching, such as the additional or synergic effects of combining other antihypertensive drugs with ACEIs leading to a higher BP reduction [43] .
At first glance, the observed significant reduction in BP (better BP control) in the ACEIs-combined group despite a significant decrease in medicine adherence (poor adherence) after switching seems to contradict the notion that poor adherence leads to suboptimal BP control [2] . However, a statistically significant reduction in adherence may not always result in clinically relevant BP control [44] .
It was not surprising to find that ARBs switching did not significantly impact on patients' hypertension-related complications in the ACEI-monotherapy group because of the small sample and tiny changes in adherence and BP in the postswitching period. In contrast, the significant reduction of the MI risk in the ACEIs-combination group could result from the significant reduction in BP after switching [45] .
Although it has been reported that cost-savings from medication switching could be potentially offset by spending elsewhere in the healthcare system [9, 15] , switching of ARBs to ACEIs in this study was not associated with any additional costs to offset the cost-saving resulted from ARBs switching to ACEIs. Recently, several generic ARBs were launched, which might moderate the observed switchingrelated cost-saving in this study. However, currently, generic ACEIs are still cheaper than generic ARBs [46] ; according to the UK national list prices [46] , the cost of 28-day treatment supply of generic candesartan, irbesartan and valsartan is 16, 41 and 148% higher than generic ramipril, respectively. Furthermore, although there was no significant difference in the median of numbers of general practitioner consultations between the preswitching and postswitching period, the total number of general practitioner consultations was higher in the postswitching period, but the total cost was lower. This difference in cost could be related to the different type and/or length of consultations (face to face vs. telephone consultations) between the preswitching and postswitching period; for instance, there was a greater proportion of telephone consultations and shorter face-toface consultations (mean duration: 11.2 vs. 12.4 min) in the postswitching period compared with the preswitching period.
Watman evaluated the impact of switching ARBs to ACEIs in 435 patients with primary hypertension [40] and reported similar findings to this study regarding insignificant changes in BP, hospitalization and overall cost-saving. However, Watman only followed up patients for 12 months and considered only drug acquisition costs and staff costs involved in implementing the switching [40] . Therefore, it did not demonstrate the complete picture of the full clinical and economic implications of switching ARBs to ACEIs. This is the only population-based study that has assessed the full clinical and economic consequences of switching from ARBs to ACEIs, considering both short-term surrogate markers (adherence and BP), longer term clinical outcomes (hypertension-related complications) and healthcare costs. The self-control design has been suggested to have higher statistical power compared with the parallel two-sample design (intervention vs. control) [47] , and this study had sufficient power to detect the significant difference in the outcomes of SBP, DBP and overall cost. It was not possible to identify the reasons for ARBs switching. Switching could occur for clinical (intolerance, treatment failure and development of other comorbid conditions [20] ) or cost-saving reasons, all rarely or inconsistently recorded in the databases. Switching because of intolerance to ARBs is considered relatively unlikely given their better [13, 48] or at least similar [12, 34] tolerability profile compared with ACEIs. Switching because of treatment failure/clinical ineffectiveness is also regarded as unlikely as ARBs and ACEIs have comparable clinical efficacy [8, 42] . ACEIs have similar or broader license indications than ARBs [49] , so it is doubtful that general practitioners would switch patients from ARBs to ACEIs in response to the development of new comorbid conditions. Therefore, after ruling out these clinical reasons, costsaving is assumed to underpin most of these switching activities. This study was limited in size by only including patients from HES-consenting practices. Nevertheless, patients from HES-consenting practices have shown to be representative of the whole CPRD registrants regarding demographics, major prescriptions and hospitalizations [19] . The number of patients included in this study was higher than the amounts reported in previous clinical trials or observational studies [40, 41, 50] , which evaluated the clinical and economic impact of antihypertensive drug switching other than ARBs to ACEIs.
Arguably, the study findings might be limited by the small number of cardiovascular events and the relatively medium follow-up period; however, it is unlikely that a longer follow-up time would have affected the results as there was no increase in BP, which is the typical, most reliable and well-evaluated surrogate marker for CVD [51] . As this study used healthcare databases, it was not possible to include the cost of implementing ARBs switching. The cost of staff involved in implementing the switching would not persist over time, whereas the overall cost-saving of ARBs switching is a continuous cost-saving generated from the chronic, lifetime use of cheaper ACEIs once switched from more expensive ARBs [40] .
It is possible that this study results might be extrapolated to other drug classes or molecules, including other antihypertensive drug classes, which, similar to ARBs and ACEIs, have comparable clinical efficacy, safety profile and dosing schedule. However, because of the complex and multifactorial nature of the switching process and disease conditions, the extrapolation of this research findings needs further investigation.
In conclusion, switching adults with hypertension from ARBs to ACEIs appeared to not compromise patients' adherence and clinical outcomes but resulted in overall cost-savings. Therefore, on this occasion and in this setting, it could be concluded that switching of ARBs to ACEIs can be considered a safe and clinical-effective cost-containment strategy, which could be used as evidence by clinicians and
